載入...
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel....
Na minha lista:
| 發表在: | N Engl J Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584549/ https://ncbi.nlm.nih.gov/pubmed/25693012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1413513 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|